NVO’s Ozempic Outshines LLY’s Mounjaro in Lowering Cardiovascular Risk
Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults…
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies’ Setback
Xenon Pharmaceuticals XENE announced that it has submitted a new drug application (NDA) to the FDA for azetukalner,…
Definium Reports Second Phase III Success in Anxiety Disorder Program
Definium Therapeutics DFTX reported positive late-stage data for DT120 (lysergide) orally disintegrating tablet (ODT) in generalized anxiety disorder…
IonQ Advances Quantum Computing With Superion 256: What’s Ahead?
IonQ IONQ has launched Superion 256, its sixth-generation quantum computing platform and the foundation for future compute products.…
FDA Accepts & Gives Priority Review to Intellia’s BLA for HAE Drug
Intellia Therapeutics NTLA announced that the FDA has accepted the biologics license application (BLA) seeking approval for lonvoguran ziclumeran…
What’s Driving Quantum Computing’s Long-Term Growth Potential?
Quantum Computing Inc. QUBT or QCi completed the acquisition of NHanced Semiconductors, Inc., a U.S.-based advanced packaging foundry,…
AAOI Benefits From Strong 800G Demand: Can It Beat LITE & COHR?
Applied Optoelectronics AAOI is benefiting from accelerating demand for 800G optical transceivers, strengthening its position against Lumentum LITE…
Oracle’s Credit Risk Nears an 18-Year High: Can AI Backlog Save Stock?
Credit rating agencies have grown increasingly cautious on Oracle ORCL as the company’s aggressive artificial intelligence buildout strains…
Does EU Approval of Wegovy Pill Change NVO’s Competitive Story?
Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of…
KEEL vs. P: Which AI Infrastructure Stock Provides an Upside?
Both Keel Infrastructure Corp. KEEL and Everpure, Inc. P are riding the AI infrastructure momentum. Keel Infrastructure is concentrated…
Can Wegovy Pill’s Rapid Uptake Give Novo Nordisk an Edge Over LLY?
Novo Nordisk NVO remains one of the dominant players in the rapidly expanding obesity treatment market. The company markets…
Can Oral Ozempic and Label Expansions Revive NVO’s Near-Term Growth?
Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic…